Early phase studies of JAK1 selective inhibitors in rheumatoid arthritis

The first approved Janus kinase (JAK) inhibitors for treatment of RA targeted more than one JAK molecule. Although this brings an advantage of simultaneous blocking of more cytokines involved in RA, it may also carry an increased risk of toxicity. Subsequently, more selective JAK inhibitors were dev...

Descripción completa

Detalles Bibliográficos
Autores principales: Avci, Ali Berkant, Feist, Eugen, Burmester, Gerd Rüdiger
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Supplement
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8098113/
https://www.ncbi.nlm.nih.gov/pubmed/33950228
http://dx.doi.org/10.1093/rheumatology/keaa893

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8098113/
https://www.ncbi.nlm.nih.gov/pubmed/33950228
http://dx.doi.org/10.1093/rheumatology/keaa893

Ejemplares similares